Rare in primary breast tumors and de novo MBC, ESR1 mutations are frequently acquired under the selective pressure of aromatase inhibitor (AI) therapy. 15 ESR1 mutations are enriched in the estrogen ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

The researchers found that median progression-free survival was 5.0 and 2.1 months with vepdegestrant and fulvestrant, respectively, among the 270 patients with ESR1 mutations (hazard ratio, 0.58).

Hamilton and colleagues stratified patients based on ESR1 mutations and visceral disease. In all, 43.3% of patients had an ESR1 mutation (136 received vepdegestrant; 134 received fulvestrant).

Out of 3256 patients screened for ESR1 mutations, 548 tested positive, and 315 were enrolled in the randomized portion of the trial. Of these, 157 were assigned to the camizestrant group and 158 ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 mutation and could benefit from switching first-line agents.

A new once-day pill made by AstraZeneca has the ability to delay breast cancer progression in those in the advanced stages along with ESR1 mutations, according to phase-3 trials conducted by the ...

Quick Take Vepdegestrant in ESR1 -Mutant Breast Cancer August 6, 2025 DOI: 10.1056/NEJMdo008080 Save ...

ESR1 mutations are a common cause of acquired resistance and are found in approximately 40% of patients in the second-line setting. 2,3,4 ...

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer Published Jun 6, 2025 7:00am EDT ...